Items which should not routinely be prescribed in primary care - oxycodone and naloxone combination product by all Sub-ICB Locations

Why it matters:

NHS England guidance states:

Oxycodone and naloxone combination product is used to treat severe pain and can also be used second line in restless legs syndrome. The opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors in the gut.

PrescQIPP CIC has issued a bulletin, which does not identify a benefit of oxycodone and naloxone in a single product over other analgesia (with laxatives if necessary).

Due to the significant cost of the oxycodone and naloxone combination product and the unclear role of the combination product in therapy compared with individual products, the joint clinical working group considered oxycodone and naloxone suitable for inclusion in this guidance.

For guidance on when prescribing may be appropriate in some exceptional circumstances, please see the full NHS England guidance document.

Description: Cost of oxycodone and naloxone combination per 1000 patients

Performance: Loading...


Tagged as: Cost Saving, NHS England - items which should not routinely be prescribed in primary care, Opioids, Pain (or browse all measures)

Sub-ICB Locations are ordered by mean percentile over the past six months. Each chart shows the results for the individual Sub-ICB Location, plus deciles across all Sub-ICB Locations in the NHS in England.

View measure for NHS England combined →

Fetching data...

Do you need help with your analysis? Don't forget to check the FAQ page, and get in touch if you have questions.